See Shionogi-Sponsored Publications

Publications

Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.

Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

  • All
  • Cefiderocol
  • Ensitrelvir
  • Zatolmilast
  • All
  • In vitro
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Real-world evidence
  • Surveillance
  • Review
  • Pharmacokinetics/Pharmaco-dynamics
  • Compatibility
  • All
  • Gram-negative infection
  • COVID-19
  • Fragile X syndrome
 
Cefiderocol
Surveillance
Gram-negative infection

In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019

Published:
2022
Authors:
Karlowsky JA, Hackel MA, Takemura M, et al.
View Publication
 
Cefiderocol
Pharmacokinetics/Pharmacodynamics
Gram-negative infection

Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects

Published:
2022
Authors:
Kawaguchi N, Katsube T, Echols R, et al.
View Publication
 
Cefiderocol
Phase 3
Gram-negative infection

Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study

Published:
2022
Authors:
Skaar EP, Echols R, Matsunaga Y, et al.
View Publication
 
Cefiderocol
Phase 3
Gram-negative infection

Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials

Published:
2022
Authors:
Nordmann P, Shields RK, Doi Y, et al.
View Publication
 
Cefiderocol
Phase 2
Phase 3
Gram-negative infection

Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective Phase 2 and Phase 3 randomised clinical studies

Published:
2022
Authors:
Paterson DL, Kinoshita M, Baba T, et al.
View Publication